Loading
IC
Ingevity Corp Stock: price and insider trades · United States
Ingevity Corp: what insiders have been doing
Ingevity Corp, classified in the Chemicals & Materials sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 47 filings signed by 20 insiders.
No insider bought on the market over the period, while 3 insiders filed 10 sales totalling €1.5M. At €332k, the sale published on 14 August 2026 by Li David H is the largest of the period (0.015% of market cap).
Compared with its exchange (5,458 companies, median 22 filings), a count of 47 filings is above the norm. Over the whole record (from 2021), the tally stands at no purchases and 13 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 1.17 bn USD and net income of -167.1 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Culp Inc and Gold.com, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
185
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€2M
13 ops. · all time
Who traded when
BuySaleDavid H. Li5 sales
Terrance M. Dyer3 sales
Ryan C. Fisher2 sales
Analyst consensus: bullish or bearish?
Analysts rate Ingevity Corp Strong Buy (bullish), based on 3 analysts. Average price target: US$89.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 11,520 of 24,148 companies
52.7
score / 100
Value51
Quality54
FCF yld11%
Earn yld-6.9%
EV/EBITDA·
ROE30%
Gross mgn40%
Net mgn-14%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$70.54
Analyst consensus
3 analystsStrong buy
US$85.00Target US$89.00(+26%)US$92.00
Income statement
RevenueUS$1.2B
Gross profitUS$461.5M40% margin
EBITDAUS$41.4M4% margin
Net income-US$167.1M4.7% margin
Valuation
PER (trailing)100.8x
PER (forward)11.7x
P/Book51.9x
Beta1.14
Balance sheet & cash
Market capUS$2.4B
Total debtUS$1.2B
Free Cash FlowUS$273.5M
Debt / Equity2636%
Profitability & ownership
ROE30.1%
ROA10.4%
% insiders0.8%
% institutions105.6%
Last declaration on 2 October 2026
Declarations185 total
405 shares@ US$71.090.0012% mcap15.5% of flowCommon StockSEC:0001575329-26-000011:0
335 shares@ US$71.090.0010% mcap21.0% of flowCommon StockSEC:0002066872-26-000008:0
5,000 shares@ US$75.730.015% mcap14.1% of flowCommon StockSEC:0001436880-26-000008:0
5,000 shares@ US$75.830.015% mcap14.1% of flowCommon StockSEC:0001436880-26-000008:1
92 shares@ US$74.710.0003% mcap0.3% of flowCommon StockSEC:0001436880-26-000008:2
5,000 shares@ US$76.620.015% mcap14.3% of flowCommon StockSEC:0001436880-26-000006:0
5,000 shares@ US$75.730.015% mcap14.1% of flowCommon StockSEC:0001436880-26-000006:1
20,092 shares@ US$77.790.062% mcap100.0% of flowCommonSEC144:0001950047-26-008035
1,698 shares@ US$77.040.0052% mcap22.6% of flowCommon StockSEC:0001668926-26-000006:0
1,397 shares@ US$73.760.0041% mcap33.8% of flowCommon StockSEC:0002017486-26-000005:0
1,312 shares@ US$73.670.0039% mcap31.7% of flowCommon StockSEC:0002017486-26-000005:1
2,709 shares@ US$73.71860.0080% mcap100.0% of flowCommonSEC144:0001950047-26-007505
3,294 shares@ US$73.260.0098% mcap42.4% of flowCommon StockSEC:0001653477-26-000041:0
168 shares@ US$73.860.0005% mcap4.1% of flowCommon StockSEC:0001653477-26-000039:0
2,063 sharesCommon StockSEC:0002142185-26-000004:0
30 shares@ US$68.570.0001% mcap6.1% of flowCommon StockSEC:0001552446-26-000003:1
266 shares@ US$68.450.0007% mcap53.6% of flowCommon StockSEC:0001552446-26-000003:0
200 shares@ US$68.530.0005% mcap40.3% of flowCommon StockSEC:0001552446-26-000003:2
1,904 shares0Common StockSEC:0001653477-26-000023:0
1,904 shares0Common StockSEC:0001531814-26-000001:0
1,904 shares0Common StockSEC:0001653477-26-000024:0
1,904 shares0Common StockSEC:0001095670-26-000001:0
1,904 shares0Common StockSEC:0001575329-26-000004:0
1,904 shares0Common StockSEC:0001580705-26-000002:0
1,904 shares0Common StockSEC:0001938475-26-000002:0
25 of 185 declarations
About Ingevity Corp
Ingevity Corp. (NYSE: NGVT) is a U.S.-listed specialty materials company headquartered in North Charleston, South Carolina, United States. The company develops advanced carbon, engineered materials, specialty polymers, and specialty chemicals for demanding industrial applications. Its business model is centered on technical differentiation, customer formulation support, and application performance rather than commodity-scale volume. Ingevity currently reports three operating segments: Performance Materials, Advanced Polymer Technologies, and Performance Chemicals. Performance Materials includes activated carbon technologies used in emissions control and filtration. Advanced Polymer Technologies includes caprolactone-based specialty polymers used in coatings, adhesives, elastomers, and related industrial applications. Performance Chemicals covers specialty chemicals and pavement technologies, including products used in agriculture, infrastructure, and road-marking applications.
Ingevity’s roots go back to the legacy operations of Westvaco and later WestRock. The company was separated into an independent public company in May 2016, giving it a long industrial heritage while allowing management to sharpen the portfolio around higher-value specialty businesses. Ingevity also emphasizes a roughly 90-year legacy of innovation tied to its underlying technology platforms. Today, the group says it operates from multiple locations worldwide, supporting a geographically diversified commercial footprint across North America and other international markets.
Read moreShow less
From a competitive standpoint, Ingevity occupies a niche position in the specialty chemicals and materials landscape. Its strengths lie in technical barriers to entry, product qualification cycles, and the ability to serve end markets where performance, reliability, and regulatory compliance matter. Key end uses include automotive components, emissions capture, asphalt paving, coatings, agrochemicals, lubricants, bioplastics, and pavement markings. This makes the company exposed to several end markets, but also gives it a portfolio of products that are embedded in mission-critical processes and infrastructure.
Recent developments highlight an active portfolio reshaping effort. In 2025 and 2026, Ingevity continued to streamline its asset base through divestitures and strategic reviews of non-core businesses, including actions tied to parts of its industrial specialties and road-markings activities. The company’s 2025 results showed resilience in the underlying business despite a volatile macro backdrop, while early 2026 updates confirmed that management remains focused on improving mix, reducing complexity, and strengthening free cash flow generation. For investors, NGVT therefore represents a specialty materials story on the NYSE with a restructuring angle: the long-term equity case depends on execution, margin discipline, and the successful repositioning of the portfolio toward higher-quality specialty applications.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
